Product Description
Mechanisms of Action: ER Agonist
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Duramed Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Other
Phase 3: Menopause
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DR-ENJ-401 | P4 |
Completed |
Other |
2009-02-01 |
|
| DR-ENJ-301 | P3 |
Completed |
Menopause |
2006-02-01 |